Our website does not fully support your browser.

We've detected that you are using an older version of Internet Explorer. Your commerce experience may be limited. Please update your browser to Internet Explorer 11 or above.

We believe this site might serve you best:

United States

United States

Language: English

Promega's Cookie Policy

Our website uses functional cookies that do not collect any personal information or track your browsing activity. When you select your country, you agree that we can place these functional cookies on your device.

Lumit™ Immunoassays:

A Novel Way to Faster, Easier Science

December 3, 2020

Virtual, 1-2pm EST

Speakers: Dan Lazar, PhD: Sr. Research Scientist Promega Corporation​​ | Nidhi Nath, PhD: Sr. Research Scientist Promega Corporation​​ | Hicham Zegzouti, PhD: Sr. Research Scientist Promega Corporation


Are you interested in more sensitive, and reproducible immunoassays? Are you currently using immunoassays, or do you plan to in the future? Join us for an interactive seminar where Promega's research scientists share how Lumit™ Immunoassays can simplify your research! We’ll start with a general overview of the technology, then break out into deep dive sessions to connect directly with R&D scientists and discuss applications of Lumit™ specific to your research.

You Will Learn

Advantages of Lumit Immunoassays over traditional immunoassays like ELISAs and Western blots

  • Simple add-mix-read protocol with no washing steps
  • Direct analyte measurement in the cell culture plate or on medium removed from cells in as little as 30 minutes
  • No immobilization to plates, beads or other surfaces required
  • Sensitive luminescence detection with wide dynamic range

Understand the different applications for Lumit™, including cellular assays, cytokine assays or build-your-own approach

Speak directly and in-depth with Promega R&D scientists about how Lumit™ can expedite and improve your workflow

Learn More About Lumit


Event Speakers


Hicham Zegzouti, Ph.D.

Senior Research Scientist 3 – Group Leader, Assay Design

Dr. Hicham Zegzouti is a Senior Research Scientist in Promega Assay Design-R&D. His group develops Assay technologies to interrogate diverse enzyme activities and cellular pathways (kinases, glycosyltransferases, and other drug targets). Dr. Zegzouti has authored 25 journal articles and book chapters, co-edited a methods book and is an inventor for one issued and 4 pending patents. 

Dan Lazar

Dan Lazar, PhD

Senior Research Scientist

Dr. Dan Lazar received his Ph.D. in biological chemistry from the University of Michigan and then completed a postdoctoral fellowship focused on cell signaling at Warner Lambert/Parke-Davis. Subsequently, he was a Team Leader and Senior Scientist at Eli Lilly within the metabolic disease drug-discovery area for well over a decade where he gained extensive experience in the development, validation and implementation of cell-based and biochemical assays for drug discovery. As a Group Leader and Senior Research Scientist at Promega, Dan and his colleagues are principally focused on delivering novel cell-based assays for the quantitative assessment of various aspects of cell health to assist academic and industrial investigators.


Nidhi Nath, Ph.D.

Senior Research Scientist 3 – Group Leader, Protein Analysis 

Dr. Nidhi Nath is a Senior Research Scientist in Promega Protein and Nucleic Acid-R&D. His group develops novel products for antibody and protein purification, analysis, and characterization. More recently, his group is developing immunoassays using novel Lumit™ platform which is a homogeneous add-and-read format based on Luminescent protein complementation.

Dr. Nath received his PhD in 1998 in Biomedical Engineering from Indian Institute of Technology, Delhi, India. Prior to joining Promega, he was a postdoctoral researcher in Dept. of Pharmacology, Univ. of Maryland and then worked as a Research Assistant Professor at Duke University, Biomedical Engineering.

Dr. Nath has authored 20 journal articles and is an inventor on three issued and 3 pending patents.